Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

The relation between PI3K/AKT signalling pathway and cancer

(2019) Saeed Noorolyai et al.   GENE

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

(2018) Andrea Visentin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma

(2018) Xiaoxiao Wang et al.   NEOPLASIA

Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal

(2018) Mixue Xie et al.   Cell Death & Disease

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

(2018) Matthew S Davids et al.   Lancet Haematology

FOXO Signaling Pathways as Therapeutic Targets in Cancer

(2017) Mohd Farhan et al.   International Journal of Biological Sciences

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

(2017) Dan A. Landau et al.   Nature Communications

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

(2017) Xiaohong Zhao et al.   Nature Communications

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors

(2017) Adam Albitar et al.   Oncotarget

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway

(2017) Roberta Alfieri et al.   Frontiers in Oncology

Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions

(2017) Jennifer L. Cultrera et al.   Cancer Control

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

(2015) Shuang Q. Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

(2015) Q. Yang et al.   CLINICAL CANCER RESEARCH

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

(2015) G S Choudhary et al.   Cell Death & Disease

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

(2014) Y Zhong et al.   LEUKEMIA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways

(2013) Juraj Bodo et al.   BRITISH JOURNAL OF HAEMATOLOGY

FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma

(2013) E. E. Santo et al.   CANCER RESEARCH

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

(2013) Mark Roschewski et al.   Nature Reviews Clinical Oncology

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

(2013) M. Pfeifer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells

(2013) H Luo et al.   Cell Death & Disease

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells

(2013) A Sharma et al.   Cell Death & Disease

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

(2012) Adrian Wiestner   JOURNAL OF CLINICAL ONCOLOGY

Akt, FoxO and regulation of apoptosis

(2011) Xinbo Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer

(2011) Hany Onsy Habashy et al.   BREAST CANCER RESEARCH AND TREATMENT

The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival

(2011) Antònia Obrador-Hevia et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

(2010) Leandro C. Cerchietti et al.   CANCER CELL

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia

(2010) S. M. Kornblau et al.   CLINICAL CANCER RESEARCH